The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Martin Tami Tillotson since 2012.
This trader's CIK number is 1539494.
At the time of last reporting, Martin Tami Tillotson was the Sr. V.P., Regulatory Affairs of Supernus Pharmaceuticals, Inc.. (stock ticker symbol SUPN).
Also see all insider trading activities at Supernus Pharmaceuticals, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2024 | SUPN | 0 | $0 | 8,000 | $223,280 | 8,000 | $73,920 |
| 2023 | SUPN | 0 | $0 | 13,235 | $421,414 | 9,600 | $194,319 |
| 2022 | SUPN | 0 | $0 | 5,000 | $164,899 | 5,000 | $39,500 |
| 2021 | SUPN | 0 | $0 | 6,250 | $193,640 | 6,250 | $81,124 |
| 2012 | SUPN | 2,500 | $12,500 | 0 | $0 | 48,125 | $120,649 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-01-10 | SUPN | Option Ex | 8,000 | 9.24 | 73,920 |
| 2024-01-10 | SUPN | Sale | 8,000 | 27.91 | 223,280 |
| 2023-08-30 | SUPN | Option Ex | 8,100 | 23.99 | 194,319 |
| 2023-08-30 | SUPN | Sale | 8,100 | 32.00 | 259,200 |
| 2023-08-25 | SUPN | Sale | 5,135 | 31.59 | 162,214 |
| 2023-02-16 | SUPN | Option Ex | 1,500 | .00 | 0 |
| 2022-08-04 | SUPN | Option Ex | 5,000 | 7.90 | 39,500 |
| 2022-08-04 | SUPN | Sale | 5,000 | 32.98 | 164,899 |
| 2021-04-13 | SUPN | Option Ex | 3,125 | 12.98 | 40,562 |
| 2021-04-14 | SUPN | Option Ex | 3,125 | 12.98 | 40,562 |
| 2021-04-13 | SUPN | Sale | 3,125 | 29.98 | 93,703 |
| 2021-04-14 | SUPN | Sale | 3,125 | 31.98 | 99,937 |
| 2012-12-12 | SUPN | Option Ex | 48,125 | 2.51 | 120,649 |
| 2012-05-04 | SUPN | Buy | 2,500 | 5.00 | 12,500 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Martin Tami Tillotson (Sr. V.P., Regulatory Affairs of Supernus Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.